Abbott Laboratories (NYSE:ABT) Updates FY 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 5.450-5.60 for the period, compared to the consensus estimate of 5.480. The company issued revenue guidance of -. Abbott Laboratories also updated its Q3 2026 guidance to 1.380-1.46 EPS.

Analysts Set New Price Targets

ABT has been the topic of several recent research reports. Citigroup upped their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday. Royal Bank Of Canada reissued an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday. Barclays decreased their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Finally, Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a research note on Wednesday, April 22nd. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.61.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $100.71 on Friday. The business has a fifty day moving average of $89.89 and a two-hundred day moving average of $102.17. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a market cap of $175.41 billion, a P/E ratio of 32.59, a price-to-earnings-growth ratio of 1.70 and a beta of 0.61. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Hedge Funds Weigh In On Abbott Laboratories

Several institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP raised its stake in shares of Abbott Laboratories by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 23,434,760 shares of the healthcare product maker’s stock valued at $2,936,141,000 after purchasing an additional 188,616 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Abbott Laboratories by 0.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,189,528 shares of the healthcare product maker’s stock valued at $1,652,517,000 after acquiring an additional 52,191 shares during the period. Amundi boosted its position in shares of Abbott Laboratories by 28.3% during the 4th quarter. Amundi now owns 8,185,642 shares of the healthcare product maker’s stock worth $1,025,578,000 after acquiring an additional 1,803,975 shares in the last quarter. Raymond James Financial Inc. raised its stake in Abbott Laboratories by 2.0% during the third quarter. Raymond James Financial Inc. now owns 5,536,178 shares of the healthcare product maker’s stock worth $741,515,000 after acquiring an additional 107,843 shares in the last quarter. Finally, California Public Employees Retirement System boosted its holdings in shares of Abbott Laboratories by 29.7% during the 4th quarter. California Public Employees Retirement System now owns 5,206,580 shares of the healthcare product maker’s stock valued at $652,332,000 after acquiring an additional 1,193,410 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.